📊 ISCO Key Takeaways
Is International Stem Cell CORP (ISCO) a Good Investment?
International Stem Cell Corporation exhibits severe financial distress with negative stockholders' equity of -$3.8M, indicating the company is technically insolvent. Despite modest revenue growth of 16.6% YoY to $6.9M, the company burns cash operationally (-$24K OCF) and has negative free cash flow of -$64K, with dangerously low liquidity ratios that threaten near-term viability.
International Stem Cell shows some top-line momentum, with revenue up 16.6% year over year and operations roughly near break-even. However, the quality of that improvement is weak because margins remain minimal, free cash flow is negative, liquidity is strained, and the balance sheet is severely impaired by negative equity. Fundamentally, this looks like a fragile business with limited financial flexibility despite modest revenue growth.
Why Buy International Stem Cell CORP Stock? ISCO Key Strengths
- Revenue growth of 16.6% YoY demonstrates demand for core products/services
- Positive operating income of $46K shows some operational profitability before capital structure effects
- Cash position of $966K provides minimal runway for operations
- Revenue grew 16.6% year over year, indicating continued demand or commercial progress
- Operating income turned slightly positive, showing the business is close to breakeven at the operating level
- Cash burn is relatively modest in the latest period compared with revenue size
ISCO Stock Risks: International Stem Cell CORP Investment Risks
- Negative stockholders' equity of -$3.8M indicates technical insolvency and existential solvency risk
- Current ratio of 0.80x and quick ratio of 0.46x show severe liquidity crisis with current liabilities exceeding current assets
- Negative free cash flow of -$64K combined with operating cash burn suggests inability to fund operations or growth without capital injection
- Interest coverage ratio of 0.4x indicates inability to service debt obligations from operating earnings
- No insider buying activity in last 90 days suggests lack of confidence from management
- Negative stockholders equity signals a highly stressed balance sheet and limits financial resilience
- Current ratio of 0.80x and quick ratio of 0.46x indicate weak short-term liquidity
- Net income and free cash flow remain negative, so profitability improvement is not yet durable
Key Metrics to Watch
- Operating cash flow trend and path to cash flow positivity
- Stockholders' equity recovery and balance sheet restructuring
- Revenue sustainability and gross margin realization if disclosed
- Cash runway duration given current burn rate
- Debt restructuring or equity infusion announcements
- Sustained positive operating cash flow and free cash flow
- Improvement in current ratio and reduction of balance sheet deficit
International Stem Cell CORP (ISCO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ISCO Profit Margin, ROE & Profitability Analysis
ISCO vs Healthcare Sector: How International Stem Cell CORP Compares
How International Stem Cell CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is International Stem Cell CORP Stock Overvalued? ISCO Valuation Analysis 2026
Based on fundamental analysis, International Stem Cell CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
International Stem Cell CORP Balance Sheet: ISCO Debt, Cash & Liquidity
ISCO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: International Stem Cell CORP's revenue has grown significantly by 27% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
ISCO Revenue Growth, EPS Growth & YoY Performance
ISCO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.2M | $57.0K | $0.00 |
| Q2 2025 | $2.3M | -$95.0K | $-0.01 |
| Q1 2025 | $2.1M | -$214.0K | $-0.03 |
| Q3 2024 | $2.0M | -$34.0K | $0.02 |
| Q2 2024 | $1.8M | -$34.0K | $-0.01 |
| Q1 2024 | $2.1M | -$34.0K | $-0.03 |
| Q3 2023 | $1.7M | -$2.0K | $0.02 |
| Q2 2023 | $1.8M | -$2.0K | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
International Stem Cell CORP Dividends, Buybacks & Capital Allocation
ISCO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for International Stem Cell CORP (CIK: 0001355790)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ISCO
What is the AI rating for ISCO?
International Stem Cell CORP (ISCO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ISCO's key strengths?
Claude: Revenue growth of 16.6% YoY demonstrates demand for core products/services. Positive operating income of $46K shows some operational profitability before capital structure effects. ChatGPT: Revenue grew 16.6% year over year, indicating continued demand or commercial progress. Operating income turned slightly positive, showing the business is close to breakeven at the operating level.
What are the risks of investing in ISCO?
Claude: Negative stockholders' equity of -$3.8M indicates technical insolvency and existential solvency risk. Current ratio of 0.80x and quick ratio of 0.46x show severe liquidity crisis with current liabilities exceeding current assets. ChatGPT: Negative stockholders equity signals a highly stressed balance sheet and limits financial resilience. Current ratio of 0.80x and quick ratio of 0.46x indicate weak short-term liquidity.
What is ISCO's revenue and growth?
International Stem Cell CORP reported revenue of $6.9M.
Does ISCO pay dividends?
International Stem Cell CORP does not currently pay dividends.
Where can I find ISCO SEC filings?
Official SEC filings for International Stem Cell CORP (CIK: 0001355790) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ISCO's EPS?
International Stem Cell CORP has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ISCO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, International Stem Cell CORP has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ISCO stock overvalued or undervalued?
Valuation metrics for ISCO: ROE of N/A (sector avg: 15%), net margin of -1.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ISCO stock in 2026?
Our dual AI analysis gives International Stem Cell CORP a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ISCO's free cash flow?
International Stem Cell CORP's operating cash flow is $-24.0K, with capital expenditures of $40.0K. FCF margin is -0.9%.
How does ISCO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.80 (avg: 2).